205 related articles for article (PubMed ID: 26927423)
1. Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors.
Simov V; Deshmukh SV; Dinsmore CJ; Elwood F; Fernandez RB; Garcia Y; Gibeau C; Gunaydin H; Jung J; Katz JD; Kraybill B; Lapointe B; Patel SB; Siu T; Su H; Young JR
Bioorg Med Chem Lett; 2016 Apr; 26(7):1803-8. PubMed ID: 26927423
[TBL] [Abstract][Full Text] [Related]
2. Novel JAK1-selective benzimidazole inhibitors with enhanced membrane permeability.
Kim H; Kim MK; Choo H; Chong Y
Bioorg Med Chem Lett; 2016 Jul; 26(14):3213-3215. PubMed ID: 27261178
[TBL] [Abstract][Full Text] [Related]
3. Benzimidazole Derivatives as Potent JAK1-Selective Inhibitors.
Kim MK; Shin H; Park KS; Kim H; Park J; Kim K; Nam J; Choo H; Chong Y
J Med Chem; 2015 Sep; 58(18):7596-602. PubMed ID: 26351728
[TBL] [Abstract][Full Text] [Related]
4. Selective JAK1 inhibitor and selective Tyk2 inhibitor patents.
Norman P
Expert Opin Ther Pat; 2012 Oct; 22(10):1233-49. PubMed ID: 22971156
[TBL] [Abstract][Full Text] [Related]
5. Identification of azabenzimidazoles as potent JAK1 selective inhibitors.
Vasbinder MM; Alimzhanov M; Augustin M; Bebernitz G; Bell K; Chuaqui C; Deegan T; Ferguson AD; Goodwin K; Huszar D; Kawatkar A; Kawatkar S; Read J; Shi J; Steinbacher S; Steuber H; Su Q; Toader D; Wang H; Woessner R; Wu A; Ye M; Zinda M
Bioorg Med Chem Lett; 2016 Jan; 26(1):60-7. PubMed ID: 26614408
[TBL] [Abstract][Full Text] [Related]
6. Fragment-Based Discovery of Pyrazolopyridones as JAK1 Inhibitors with Excellent Subtype Selectivity.
Hansen BB; Jepsen TH; Larsen M; Sindet R; Vifian T; Burhardt MN; Larsen J; Seitzberg JG; Carnerup MA; Jerre A; Mølck C; Lovato P; Rai S; Nasipireddy VR; Ritzén A
J Med Chem; 2020 Jul; 63(13):7008-7032. PubMed ID: 32462873
[TBL] [Abstract][Full Text] [Related]
7. Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3.
Malerich JP; Lam JS; Hart B; Fine RM; Klebansky B; Tanga MJ; D'Andrea A
Bioorg Med Chem Lett; 2010 Dec; 20(24):7454-7. PubMed ID: 21106455
[TBL] [Abstract][Full Text] [Related]
8. 9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitors.
Zimmermann K; Sang X; Mastalerz HA; Johnson WL; Zhang G; Liu Q; Batt D; Lombardo LJ; Vyas D; Trainor GL; Tokarski JS; Lorenzi MV; You D; Gottardis MM; Lippy J; Khan J; Sack JS; Purandare AV
Bioorg Med Chem Lett; 2015 Jul; 25(14):2809-12. PubMed ID: 25987372
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2(1H)-one derivatives as novel JAK inhibitors.
Yamagishi H; Shirakami S; Nakajima Y; Tanaka A; Takahashi F; Hamaguchi H; Hatanaka K; Moritomo A; Inami M; Higashi Y; Inoue T
Bioorg Med Chem; 2015 Aug; 23(15):4846-4859. PubMed ID: 26059596
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Dymock BW; See CS
Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
[TBL] [Abstract][Full Text] [Related]
11. The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3.
Lee SM; Yoon KB; Lee HJ; Kim J; Chung YK; Cho WJ; Mukai C; Choi S; Kang KW; Han SY; Ko H; Kim YC
Bioorg Med Chem; 2016 Nov; 24(21):5036-5046. PubMed ID: 27555284
[TBL] [Abstract][Full Text] [Related]
12. Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.
Kulagowski JJ; Blair W; Bull RJ; Chang C; Deshmukh G; Dyke HJ; Eigenbrot C; Ghilardi N; Gibbons P; Harrison TK; Hewitt PR; Liimatta M; Hurley CA; Johnson A; Johnson T; Kenny JR; Bir Kohli P; Maxey RJ; Mendonca R; Mortara K; Murray J; Narukulla R; Shia S; Steffek M; Ubhayakar S; Ultsch M; van Abbema A; Ward SI; Waszkowycz B; Zak M
J Med Chem; 2012 Jun; 55(12):5901-21. PubMed ID: 22591402
[TBL] [Abstract][Full Text] [Related]
13. Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.
Menet CJ; Fletcher SR; Van Lommen G; Geney R; Blanc J; Smits K; Jouannigot N; Deprez P; van der Aar EM; Clement-Lacroix P; Lepescheux L; Galien R; Vayssiere B; Nelles L; Christophe T; Brys R; Uhring M; Ciesielski F; Van Rompaey L
J Med Chem; 2014 Nov; 57(22):9323-42. PubMed ID: 25369270
[TBL] [Abstract][Full Text] [Related]
14. Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains.
Williams NK; Bamert RS; Patel O; Wang C; Walden PM; Wilks AF; Fantino E; Rossjohn J; Lucet IS
J Mol Biol; 2009 Mar; 387(1):219-32. PubMed ID: 19361440
[TBL] [Abstract][Full Text] [Related]
15. Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2.
Labadie S; Dragovich PS; Barrett K; Blair WS; Bergeron P; Chang C; Deshmukh G; Eigenbrot C; Ghilardi N; Gibbons P; Hurley CA; Johnson A; Kenny JR; Kohli PB; Kulagowski JJ; Liimatta M; Lupardus PJ; Mendonca R; Murray JM; Pulk R; Shia S; Steffek M; Ubhayakar S; Ultsch M; van Abbema A; Ward S; Zak M
Bioorg Med Chem Lett; 2012 Dec; 22(24):7627-33. PubMed ID: 23107482
[TBL] [Abstract][Full Text] [Related]
16. Discovery of potent and efficacious pyrrolopyridazines as dual JAK1/3 inhibitors.
Hynes J; Wu H; Kempson J; Duan JJ; Lu Z; Jiang B; Stachura S; Tokarski JS; Sack JS; Khan JA; Lippy JS; Zhang RF; Pitt S; Shen G; Gillooly K; McIntyre K; Carter PH; Barrish JC; Nadler SG; Salter-Cid LM; Fura A; Schieven GL; Pitts WJ; Wrobleski ST
Bioorg Med Chem Lett; 2017 Jul; 27(14):3101-3106. PubMed ID: 28539220
[TBL] [Abstract][Full Text] [Related]
17. Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitors.
Duan JJ; Lu Z; Jiang B; Yang BV; Doweyko LM; Nirschl DS; Haque LE; Lin S; Brown G; Hynes J; Tokarski JS; Sack JS; Khan J; Lippy JS; Zhang RF; Pitt S; Shen G; Pitts WJ; Carter PH; Barrish JC; Nadler SG; Salter-Cid LM; McKinnon M; Fura A; Schieven GL; Wrobleski ST
Bioorg Med Chem Lett; 2014 Dec; 24(24):5721-5726. PubMed ID: 25453808
[TBL] [Abstract][Full Text] [Related]
18. Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6.
Chrencik JE; Patny A; Leung IK; Korniski B; Emmons TL; Hall T; Weinberg RA; Gormley JA; Williams JM; Day JE; Hirsch JL; Kiefer JR; Leone JW; Fischer HD; Sommers CD; Huang HC; Jacobsen EJ; Tenbrink RE; Tomasselli AG; Benson TE
J Mol Biol; 2010 Jul; 400(3):413-33. PubMed ID: 20478313
[TBL] [Abstract][Full Text] [Related]
19. Structure activity optimization of 6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyrazines as Jak1 kinase inhibitors.
Friedman M; Frank KE; Aguirre A; Argiriadi MA; Davis H; Edmunds JJ; George DM; George JS; Goedken E; Fiamengo B; Hyland D; Li B; Murtaza A; Morytko M; Somal G; Stewart K; Tarcsa E; Van Epps S; Voss J; Wang L; Woller K; Wishart N
Bioorg Med Chem Lett; 2015 Oct; 25(20):4399-404. PubMed ID: 26372653
[TBL] [Abstract][Full Text] [Related]
20. 3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo models.
Soth M; Hermann JC; Yee C; Alam M; Barnett JW; Berry P; Browner MF; Frank K; Frauchiger S; Harris S; He Y; Hekmat-Nejad M; Hendricks T; Henningsen R; Hilgenkamp R; Ho H; Hoffman A; Hsu PY; Hu DQ; Itano A; Jaime-Figueroa S; Jahangir A; Jin S; Kuglstatter A; Kutach AK; Liao C; Lynch S; Menke J; Niu L; Patel V; Railkar A; Roy D; Shao A; Shaw D; Steiner S; Sun Y; Tan SL; Wang S; Vu MD
J Med Chem; 2013 Jan; 56(1):345-56. PubMed ID: 23214979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]